Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study건강한 성인에서 이종 및 동종 불활성화 및 아데노바이러스 매개 COVID-19 백신 요법의 안전성 및 면역원성: 전향적 코호트 연구Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Adults adverse event adverse events Antibody Response AstraZeneca ChAdOx1 ChAdOx1-S circulating variants combinations CoronaVac country COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Efficacy Evidence evidence of followed by group groups healthy Heterologous heterologous adenoviral vector heterologous vaccine homologous IgA response immune response immune responses immunized immunogenicity inactivated Inactivated vaccine interferon gamma Mild neutralizing activities Neutralizing activity prospective cohort study reactogenicity Receptor-binding domain referred to regimen Safety Serious Adverse Event Serious Adverse Events supply shortage vaccination Vaccine variants variants of concern Viral viral vectored. wild-type [DOI] 10.1080/21645515.2022.2029111 PMC 바로가기 [Article Type] Article
Vaccine Side Effects in Health Care Workers after Vaccination against SARS-CoV-2: Data from TüSeRe:exact StudyArticle Published on 2022-12-252023-07-11 Journal: Viruses [Category] COVID19(2023년), [키워드] adverse event COVID-19 reactogenicity vaccine. [DOI] 10.3390/v15010065 PMC 바로가기
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialArticle Published on 2022-12-012022-10-06 Journal: The Lancet Regional Health - Western Pacific [Category] 진단, [키워드] acute respiratory syndrome Administered Adults adverse event AEs age analysis assessment assigned BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine China Chinese clinical trial Complete Completed conducted coronavirus COVID-19 development dose double-blind Efficacy and safety enrolled Follow-up geometric mean titer GMT GMTs Han Chinese healthy immune response immunogenicity immunogenicity endpoint Inc independent individual injection intramuscular Intramuscular injection investigators Laboratory parameters management messenger Messenger RNA Mild moderate mRNA vaccine Neutralising Antibodies neutralising antibody of BNT162b2 participant Participants pharmaceutical Placebo placebo-controlled trial randomisation randomised Randomly reactogenicity receive recipients recruited reduced remained reported resolved Result robust Safety SARS-CoV-2 SARS-CoV-2 variant SCR second dose sera serious AE seroconversion rate severity Shanghai Sponsor statisticians stratified T-cell Response the placebo group Tolerability Treatment Trial utilised vaccination vaccination. vaccine administration were blinded [DOI] 10.1016/j.lanwpc.2022.100586 PMC 바로가기 [Article Type] Article
Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccinesCoronaVac 및 ChAdox1 nCov-19(AZD1222) 백신으로 이종 프라임-부스트 백신 접종 후 면역원성 및 반응성Article Published on 2022-11-302022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, 진단, [키워드] 95% CI 95% confidence interval Administered age age and sex antibody assigned AZD1222 binding domain booster dose Care ChAdOx1 nCoV-19 Cohort cohorts Combination Concentration control group CoronaVac COVID-19 COVID-19 pandemic effective elicited enrolled finding geometric mean ratio GMR Health Heterologous heterologous prime-boost homologous immune response immunogenicity indicated mass participant primary endpoint prime-boost interval RBD reactogenicity robust Safe the median vaccination Vaccine vaccine administration vaccine combination. while [DOI] 10.1080/21645515.2022.2052525 PMC 바로가기 [Article Type] Article
Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster VaccineClinical Trial Published on 2022-11-282023-06-01 Journal: The Journal of Infectious Diseases [Category] Fulltext, 두창, 수두, 홍역, [키워드] antibodies AS01 reactogenicity Recombinant zoster vaccine. T cells [DOI] 10.1093/infdis/jiab536 PMC 바로가기 [Article Type] Clinical Trial
Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of AgeArticle Published on 2022-11-032022-11-15 Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 변종, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Administered administration Adults Adverse age assigned authority B.1.1.529 children circulating Cohort cohorts coronavirus coronavirus disease criteria determine development dose duration of follow-up Efficacy elicited evaluate evaluated event geometric mean concentration immune response incidence Infection injection median Month mRNA-1273 mRNA-1273 vaccine neutralizing antibody observer-blinded open label Part phase 3 trial Placebo placebo-controlled predominant Randomly reactogenicity receive Safe Secondary objective selected the vaccine Trial Vaccine variant Year [DOI] 10.1056/NEJMoa2209367 PMC 바로가기
Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunityArticle Published on 2022-11-012022-11-15 Journal: Annals of allergy, asthma & immunology : official [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] antibody Antibody Response Autoimmune clinical trial clinician Combination Comorbidities coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine criteria detectable Diagnosis Evidence Factor healthy controls immune immune dysregulation Immunity immunodeficiency immunogenic individuals literature Messenger RNA Patient performed reactogenicity response Safe Safety SARS-CoV-2 Serious Adverse Events subjects T cell response vaccination Vaccinations Vaccine [DOI] 10.1016/j.anai.2022.06.009 PMC 바로가기
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort studyArticle Published on 2022-10-272022-11-15 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI Ad26.COV2.S Ad26.COV2.S vaccine age Analysis anti-SARS-CoV-2 Anti-spike antibody Antibody Response Antiretroviral therapy approved assays BNT162b2 CD4+ T-cell CD8+ T-cell ChAdOx1-S comparable Concentration conducted Control controls COVID-19 defined ELISPOT Endpoint Environment Final generally mild geometric HIV HIV-negative IFN-γ immunogenic immunogenicity Increased IQR less maintain male marker median age mRNA vaccination mRNA vaccine mRNA-1273 mRNA-based vaccines Netherland Netherlands of BNT162b2 PLWH predicted primary endpoint prospective cohort study Public reactogenicity receiving recipients reduced Registered remained required response SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 spike peptide SARS-CoV-2 vaccination SARS-CoV-2 vaccine secondary Serious Adverse Events serological response Sex suppressed T-cell Response the median the vaccine Trial vaccination Vaccine vaccine group Viral load with HIV [DOI] 10.1371/journal.pmed.1003979 PMC 바로가기
‘Mix and Match’ vaccination: Is dengue next?Article Published on 2022-10-262022-11-15 Journal: Vaccine [Category] COVID19(2023년), SARS, 진단, [키워드] 'Mix and match' Antigen approach benefit boost breadth cellular Cellular responses Combination COVID-19 COVID-19 pandemic demonstrated Dengue dengue virus Dengvaxia dose effective Efficacy evaluated help Heterologous HIV homologous Human Humoral immunity Immunity immunization Impact Increased immunogenicity induce match overcome priming reactogenicity regimen reported response SARS-CoV-2 SARS-CoV-2 vaccine sequence severity significantly study participant T cell TAK-003 the vaccine Trial trials TV003 vaccination Vaccine vaccine. Vaccines [DOI] 10.1016/j.vaccine.2022.09.007 PMC 바로가기
Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, PeruArticle Published on 2022-10-172022-11-15 Journal: PLoS ONE [Category] 진단, [키워드] administration ANCOVA anti-SARS-CoV-2 IgG antibody BBIBP-CorV BNT162b2 BNT162b2 vaccine booster conducted COVID-19 infection COVID-19 vaccine dose Elderly patient evaluated geometric geometric mean ratio HCW healthcare worker Heterologous heterologous vaccine homologous IgG IgG antibody IgG level immunized immunogenic immunogenicity increase in median mRNA vaccine National of BNT162b2 participant Pfizer produced prospective cohort study reactogenic reactogenicity regimen regressions Safe significantly Sinopharm two group vaccination Vaccine vaccine for COVID-19 was measured [DOI] 10.1371/journal.pone.0268419 PMC 바로가기